MARKET

ENGNW

ENGNW

Forbion European Acquisition Corp
NASDAQ
2.705
+0.215
+8.63%
Opening 11:21 12/19 EST
OPEN
2.750
PREV CLOSE
2.490
HIGH
2.750
LOW
2.588
VOLUME
825
TURNOVER
--
52 WEEK HIGH
3.800
52 WEEK LOW
0.5100
MARKET CAP
--
P/E (TTM)
-1.4232
1D
5D
1M
3M
1Y
5Y
1D
enGene Reports 62% Complete Response Rate for Detalimogene in Bladder Cancer Trial
Reuters · 12/02 12:47
ENGENE’S DETALIMOGENE SELECTED FOR FDA MANUFACTURING PILOT PROGRAM TO SUPPORT MANUFACTURING READINESS
Reuters · 12/02 12:30
ENGENE HOLDINGS - FDA SELECTS DETALIMOGENE VORAPLASMID TO PARTICIPATE IN CHEMISTRY, MANUFACTURING, & CONTROLS DEVELOPMENT & READINESS PILOT PPROGRAM
Reuters · 12/02 12:30
enGene Holdings Inc. to Present at Piper Sandler 37th Annual Healthcare Conference
Reuters · 11/25 12:30
ENGENE HOLDINGS INC <ENGN.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $19 FROM $21
Reuters · 11/14 12:21
ENGENE HOLDINGS INC - PRICING OF 12,558,823 COMMON SHARES AT A PUBLIC OFFERING PRICE OF $8.50 PER SHARE
Reuters · 11/13 05:27
ENGENE HOLDINGS FILES FOR OFFERING OF COMMON SHARES, SIZE NOT DISCLOSED - SEC FILING
Reuters · 11/12 21:53
ENGENE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
Reuters · 11/12 21:01
More
About ENGNW
enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Webull offers enGene Holdings Inc stock information, including NASDAQ: ENGNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENGNW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ENGNW stock methods without spending real money on the virtual paper trading platform.